BOULDER, Colo., Oct. 29, 2012 /PRNewswire/ -- Array BioPharma Inc. ARRY today reported results for the first quarter of its fiscal year ending June 30, 2013.
Array continues its evolution into a late-stage development company, with five products approaching Phase 3 decisions by the end of calendar year 2013. These include two wholly-owned programs: ARRY-614 and ARRY-520, and three partnered programs: selumetinib (with AstraZeneca), MEK162 (with Novartis) and danoprevir (with InterMune/Roche).
